TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03419364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: 2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: 2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: 2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
Study: NCT03846102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaïne for injection 7.5 mg/kg diluted with Sodium Chloride 0,9%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0,9% for injection/infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 500 milligram tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 500 milligram tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine 1 mg/ml solution for infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Morphine 1 mg/ml solution for infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block with Levobupivacaine
Description: Ultrasound guided Fascia Iliaca Compartment Block with levobupivacaine placed in the emergency department by an emergency physician.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fascia Iliaca Compartment Block with placebo
Description: Ultrasound guided Fascia Iliaca Compartment Block with placebo placed in the emergency department by an emergency physician.
Study: NCT01901107

Intervention type: DRUG
Intervention: Kiklin capsules
Description: oral
Study: NCT01216930

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT02660814

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: 1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: 1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gingival crevicular fluid collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gingival crevicular fluid collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method.
Study: NCT02775955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX0041
Description: Active
Study: NCT02904876

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusion Magnetic Resonance Imaging at 6 months
Description: 2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
Study: NCT01407081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Cognitive Strategy Training
Description: The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
Study: NCT03659422

Intervention type: OTHER
Group type: OTHER
Intervention: Modified Paleolithic diet
Description: The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
Study: NCT01989143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06480605
Description: Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06480605
Description: Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06480605
Description: Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
Study: NCT03613805

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G5-Eversense
Description: Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eversense-Dexcom G5
Description: Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously
Study: NCT01435863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study: NCT02475785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFRD and mini plates group
Description: FFRD direct loading over mini plates inserted in the mandibular symphysis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional FFRD
Description: FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
Study: NCT00552084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Fish oil supplements 4 gms will be taken daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplements will be taken daily for 24 weeks.
Study: NCT02946918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily
Study: NCT02064543

Intervention type: OTHER
Intervention: GAITRite
Description: mobility test assessing gait parameters

Intervention type: OTHER
Intervention: ADPM
Description: mobility test assessing gait parameters
Study: NCT04225988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release tacrolimus
Description: Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate-release tacrolimus
Description: Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.
Study: NCT00316810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Day 0: Campath 30 mg i.v. infusion over 3-6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit Anti-Human Thymocyte Globulin
Description: Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
Study: NCT01525602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 tablets, 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 tablets, 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 tablets, 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV
Study: NCT03062462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 5-7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 5-7 days
Study: NCT02651935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellivent ASV
Description: Automated Invasive mechanical ventilation and weaning strategy
Study: NCT00566579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Double freezing technique
Study: NCT00652782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofyline
Description: rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofyline
Description: rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofyline
Description: rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofyline
Description: rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator Placebo (unspecified)
Description: Matching placebo for rolofyline IV QD; 3 days
Study: NCT03979196

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Management
Description: Admission for a minimum of three days, administration of betamethasone, and clinical reassessment by obstetrician after three days. After the initial three day admission, further management will be at the discretion of their obstetrician who will continue their care and decide if further admissions are needed.~Weekly cervical length assessment will be performed until 28 weeks and patient readmission will be decided by their Obstetrician.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Management
Description: Avoid heavy lifting and core exercise, avoid intercourse, weekly assessment of cervical length by ultrasound and administration of betamethasone. Patients will continue with outpatient management for the remainder of their pregnancy with no admission unless the patient develops contractions, PPROM, bleeding, or the cervix is dilated to ≥1cm.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected.
Study: NCT03280134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymph node dissection (ALND)
Description: If the patients had predictive nSLN+, need further axillary lymph node dissection.
Study: NCT01620567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: avocado
Description: 1 avocado/day for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: potato or chickpea
Description: 1 cup potatoes or chickpeas/day for 6 months
Study: NCT02465840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: custom-made dynamic hand splint
Description: custom-made dynamic splinting with more early active exercises intervention.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: custom-made protective hand splint
Description: Immobilization splint with gentle ROM exercises

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physical therapy and occupational therapy
Description: both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy and occupational therapy
Description: both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
Study: NCT00486421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1mg/kg/d PO, taper to off by 8 weeks
Study: NCT01690884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
Study: NCT02874495

Intervention type: BEHAVIORAL
Intervention: Heart Rate Variability
Description: During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).

Intervention type: BEHAVIORAL
Intervention: Heart Rate Variability
Description: During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
Study: NCT01908114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Community mobilization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Community mobilization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA
Study: NCT03304080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg orally daily, day 1 to day 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
Study: NCT01690884

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adenosine
Description: Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
Study: NCT04620187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab (T) emtansine (T-DM1)
Description: Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard of Care Radiotherapy
Description: Radiotherapy to shrink or kill tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Intravenous injection
Study: NCT02172625

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protandim Dietary Supplement
Description: This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
Study: NCT04394364

Intervention type: DEVICE
Intervention: Bispectral index
Description: The BIS monitor will be attached to patients' forehead before anesthetized and kept until the end of the surgery
Study: NCT00799643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate
Description: Salsalate 3.5 g/d orally, divided dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salsalate Placebo
Study: NCT03081390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance testing
Description: An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance testing
Description: An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance testing
Description: An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance testing
Description: An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin conductance & cold pressor test
Description: Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin conductance & cold pressor test
Description: Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin conductance & cold pressor test
Description: Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
Study: NCT04280744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Patient preferred song will be provided in a sedative manor (e.g., 60-80 beats per minute) using live music (singing with guitar accompaniment) by a board certified music therapist.
Study: NCT02935179

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White sweet potato diet
Description: The diet were supplied 516 kcal daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White sweet potato diet
Description: The diet were supplied 516 kcal daily
Study: NCT01654120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: SC, 1.8mg,QD, six months to one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: SC, will be titrated during the study, 4 times a day, 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: SC, will be titrated during the study, 4 times a day, 1 year